litlas
ログインアカウント作成

Mark C. Genovese

1991–2026 年に発表

別表記
Mark C Genovese
131
論文数
28,679
被引用数
89
h 指数
128
i10 指数

被引用数

Mark C. Genovese の年別被引用数1974 年: 被引用 1 件1986 年: 被引用 4 件1987 年: 被引用 3 件1991 年: 被引用 2 件1992 年: 被引用 1 件1993 年: 被引用 2 件1994 年: 被引用 3 件1995 年: 被引用 3 件1996 年: 被引用 4 件1997 年: 被引用 4 件1998 年: 被引用 7 件1999 年: 被引用 5 件2000 年: 被引用 10 件2001 年: 被引用 56 件2002 年: 被引用 147 件2003 年: 被引用 198 件2004 年: 被引用 196 件2005 年: 被引用 187 件2006 年: 被引用 215 件2007 年: 被引用 196 件2008 年: 被引用 235 件2009 年: 被引用 272 件2010 年: 被引用 328 件2011 年: 被引用 315 件2012 年: 被引用 293 件2013 年: 被引用 282 件2014 年: 被引用 257 件2015 年: 被引用 310 件2016 年: 被引用 256 件2017 年: 被引用 334 件2018 年: 被引用 308 件2019 年: 被引用 788 件2020 年: 被引用 1,051 件2021 年: 被引用 887 件2022 年: 被引用 743 件2023 年: 被引用 543 件2024 年: 被引用 783 件2025 年: 被引用 390 件2026 年: 被引用 7 件1975〜1985 年は被引用が無いため表示していません1988〜1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,910 件、この内訳の 24.1%イギリス: 引用元論文 1,076 件、この内訳の 8.9%ドイツ: 引用元論文 761 件、この内訳の 6.3%中国: 引用元論文 621 件、この内訳の 5.1%イタリア: 引用元論文 542 件、この内訳の 4.5%カナダ: 引用元論文 536 件、この内訳の 4.4%フランス: 引用元論文 527 件、この内訳の 4.4%日本: 引用元論文 494 件、この内訳の 4.1%オランダ: 引用元論文 480 件、この内訳の 4%スペイン: 引用元論文 344 件、この内訳の 2.9%オーストラリア: 引用元論文 331 件、この内訳の 2.7%スイス: 引用元論文 316 件、この内訳の 2.6%
0%24.1%その他 26%

機関

分野

  • Medicine70.4%
  • Immunology and Microbiology17.3%
  • Biochemistry, Genetics and Molecular Biology8.1%
  • Neuroscience1.7%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Computer Science0.4%
  • その他1.5%

トピック

  • Rheumatoid Arthritis Research and Therapies13.3%
  • Systemic Lupus Erythematosus Research5.8%
  • Spondyloarthritis Studies and Treatments5.7%
  • Autoimmune and Inflammatory Disorders Research4.9%
  • T-cell and B-cell Immunology4%
  • Psoriasis: Treatment and Pathogenesis3.5%
  • その他62.8%

共著者

全論文

検索で開く
  1. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

    著者: Liana Fraenkel, Joan M. Bathon, Bryant R. England, E. William St. Clair, Thurayya Arayssi, Kristine Carandang, Kevin D. Deane, Mark C. Genovese, K. Huston, Gail S. Kerr, Joel M. Kremer, Mary C. Nakamura, Linda Russell, Jasvinder A. Singh, Benjamin J. Smith, Jeffrey A. Sparks, Shilpa Venkatachalam, Michael E. Weinblatt, Mounir Al‐Gibbawi, Joshua F. Baker, Kamil E. Barbour, Jennifer L. Barton, Laura C. Cappelli, Fatimah Chamseddine, Michael George, Sindhu R. Johnson, Lara A Kahale, Basil S. Karam, Assem M. Khamis, Iris Navarro‐Millán, Reza Mirza, Pascale Schwab, Namrata Singh, Marat Turgunbaev, Amy S. Turner, Sally Yaacoub, Elie A. Akl - Arthritis & Rheumatology 2021 被引用: 1,284

  2. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

    著者: Roy Fleischmann, Aileen L. Pangan, In‐Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J.K. Östör, Yihan Li, Yijie Zhou, Ahmed A. Othman, Mark C. Genovese - Arthritis & Rheumatology 2019 被引用: 436

  3. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

    著者: Mark C. Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert‐Roth, Ying Zhang, Yijie Zhou, Mohamed‐Eslam F. Mohamed, Sebastian Meerwein, Aileen L. Pangan - The Lancet 2018 被引用: 443

  4. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

    著者: Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J. Simón, Herbert S. B. Baraf, Uma Kumar, F. Matzkies, Beatrix Bartók, Lei Ye, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Mark C. Genovese, Neelufar Mozaffarian, Robert Landewé, Sang‐Cheol Bae, Edward C. Keystone, Peter Nash - Annals of the Rheumatic Diseases 2021 被引用: 247

  5. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

    著者: Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg, Neelufar Mozaffarian, Beatrix Bartók, F. Matzkies, Jie Gao, Ying Guo, Chantal Tasset, John S. Sundy, Kurt de Vlam, David Walker, Tsutomu Takeuchi - JAMA 2019 被引用: 327

  6. Baricitinib in Patients with Refractory Rheumatoid Arthritis

    著者: Mark C. Genovese, Joel Kremer, Omid Zamani, Charles Ludivico, Marek Krogulec, Li Xie, Scott D. Beattie, Alisa E. Koch, Tracy Cardillo, Terence Rooney, William L. Macias, Stephanie de Bono, Douglas Schlichting, Josef S Smolen - New England Journal of Medicine 2016 被引用: 621

  7. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

    著者: Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis - Arthritis & Rheumatism 2006 被引用: 1,640

  8. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

    著者: Roy Fleischmann, Mark C. Genovese, Jeffrey Enejosa, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J.K. Östör, Yihan Li, In‐Ho Song - Annals of the Rheumatic Diseases 2019 被引用: 174

  9. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

    著者: Josef S Smolen, Mark C. Genovese, Tsutomu Takeuchi, David L. Hyslop, William L. Macias, Terence Rooney, Lei Chen, Christina Dickson, Jennifer Riddle Camp, Tracy Cardillo, Taeko Ishii, Kevin Winthrop - The Journal of Rheumatology 2018 被引用: 259

  10. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

    著者: Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark C. Genovese, Khalid Ahmed, Jeffrey Alper, N Barkham, Ralph E. Bennett, Francisco J. Blanco, Ricardo Blanco Alonso, Howard Blumstein, Michael S. Brooks, Gerd‐Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der‐Yuan Chen, Melvin Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, José Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilová, Rita M. Egan, Andrea Everding, E. Galíndez, Mark C. Genovese, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu‐Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz Korkosz, Roshan Kotha, Joel M. Kremer, C Lue, José Luís Marenco de la Fuente, Helena Marzo‐Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama Nandagudi, Peter Nash, Antonio Fernández‐Nebro, C. Michael Neuwelt, Ana‐Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell‐Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen‐Fang Tsai, Anthony Turkiewicz, L. Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielińska - The Lancet 2017 被引用: 405

  11. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study

    著者: Mark C. Genovese, Norman Gaylis, David Sikes, Alan Kivitz, Diane Horowitz, Charles Peterfy, Emmett V. Glass, Yaakov A. Levine, David Chernoff - The Lancet Rheumatology 2020 被引用: 115

  12. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

    著者: Edward Keystone, Peter C. Taylor, Edit Drescher, Douglas Schlichting, Scott D. Beattie, Pierre‐Yves Berclaz, Chin H. Lee, Rosanne Fidelus-Gort, Monica Luchi, Terence Rooney, William L. Macias, Mark C. Genovese - Annals of the Rheumatic Diseases 2014 被引用: 282

  13. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

    著者: Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, F. Matzkies, Mark C. Genovese, Deyuan Jiang, Kun Chen, Beatrix Bartók, Angelika Jahreis, R. Besuyen, Gerd R Burmester, Jacques‐Eric Gottenberg - Annals of the Rheumatic Diseases 2021 被引用: 79

  14. Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial

    著者: Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto, Rui Zhao, Joshua Galanter, Chin Lee, Julie Rae, Balázs István Tóth, Nandhini Ramamoorthi, Jason A. Hackney, Alberto Berman, Nemanja Damjanov, Dmytro Fedkov, Sławomir Jeka, Leslie W. Chinn, Michael J. Townsend, Alyssa Morimoto, Mark C. Genovese - Arthritis & Rheumatology 2020 被引用: 118

  15. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

    著者: Mark C. Genovese, Jean‐Claude Becker, Michael Schiff, Michael E. Luggen, Yvonne Sherrer, Joel Kremer, C. Birbara, J. Box, Kannan Natarajan, Isaac Nuamah, Tracy Li, Richard Aranda, David Hagerty, Maxime Dougados - New England Journal of Medicine 2005 被引用: 1,245

  16. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

    著者: Joel M. Kremer, Zhanguo Li, Stephen Hall, Roy Fleischmann, Mark C. Genovese, E. Martín‐Mola, John D. Isaacs, David Gruben, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, Tamás Koncz, Richard J. Riese, John Bradley - Annals of Internal Medicine 2013 被引用: 447

  17. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study

    著者: Sara Marsal, Hèctor Corominas, Juan José de Agustín, Carolina Pérez-García, María López‐Lasanta, Helena Borrell, Dèlia Reina, Raimón Sanmartí, Javier Narváez, Clara Franco‐Jarava, Charles Peterfy, José Antonio Narváez, Vivek Kumar Sharma, Konstantinos Alataris, Mark C. Genovese, Matthew Baker - The Lancet Rheumatology 2021 被引用: 70

  18. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome

    著者: E. William St. Clair, Alan N. Baer, Chungwen Wei, Ghaith Noaiseh, A. L. Parke, Andreea Coca, Tammy O. Utset, Mark C. Genovese, Daniel J. Wallace, James McNamara, Karen Boyle, Lynette Keyes‐Elstein, Jeffrey L. Browning, Nathalie Franchimont, Kira Smith, Joel M. Guthridge, Igñacio Sanz, Judith A. James - Arthritis & Rheumatology 2018 被引用: 91

  19. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

    著者: Mark C. Genovese, Stanley Cohen, Larry W. Moreland, D. Lium, Sean Robbins, Richard Newmark, Pirow Bekker, for the 20000223 Study Group - Arthritis & Rheumatism 2004 被引用: 522

  20. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

    著者: Xavier Montalbán, Daniel J. Wallace, Mark C. Genovese, Davorka Tomic, Dana Parsons‐Rich, Claire Le Bolay, Amy Kao, Hans Guehring - Journal of Neurology Neurosurgery & Psychiatry 2022 被引用: 33

  21. Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

    著者: Mark C. Genovese, Josef S Smolen, Michael E. Weinblatt, Gerd R Burmester, Sebastian Meerwein, Heidi S. Camp, Li Wang, Ahmed A. Othman, Nasser Khan, Aileen L. Pangan, Steven Jungerwirth - Arthritis & Rheumatology 2016 被引用: 201

  22. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis

    著者: Kevin Winthrop, Masayoshi Harigai, Mark C. Genovese, Stephen Lindsey, Tsutomu Takeuchi, Roy Fleischmann, John Bradley, Nicole L Byers, David L. Hyslop, Maher Issa, Atsushi Nishikawa, Terence Rooney, Sarah Witt, Christina Dickson, Josef S Smolen, Maxime Dougados - Annals of the Rheumatic Diseases 2020 被引用: 93

  23. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

    著者: Mark C. Genovese, Eduardo Mysler, Tetsuya Tomita, Kim Papp, Carlo Salvarani, Sergio Schwartzman, Gaia Gallo, Himanshu J. Patel, Jeffrey Lisse, Andris Kronbergs, Soyi Liu Leage, David H. Adams, Wen Xu, Helena Marzo‐Ortega, Mark Lebwohl - Lara D. Veeken 2020 被引用: 71

  24. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

    著者: Matthew Baker, Yashaar Chaichian, Mark C. Genovese, Vimal K. Derebail, Panduranga S. Rao, Winn Chatham, M Bubb, Sam Lim, Hooman Hajian, Oksana Gurtovaya, Uptal D. Patel, James A. Tumlin - RMD Open 2020 被引用: 43